chlorzoxazone has been researched along with Liver Diseases, Alcoholic in 3 studies
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.
Liver Diseases, Alcoholic: Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlormethiazole inhibited the increase in the ethanol-induced CYP2E1 activity in vivo, as measured by chlorzoxazone 6-hydroxylation, but did not affect the level of CYP2E1 apoprotein." | 1.31 | Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. ( Donohue, TM; Fang, C; French, BA; French, SW; Fu, P; Gouillon, Z; Hagbjork, AL; Ingelman-Sundberg, M; Li, J; Lucas, D, 2000) |
| "001) and other pharmacokinetic parameters." | 1.30 | Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. ( Basu, P; Kessova, I; Lieber, CS; Mishin, VM; Oneta, CM; Rosman, AS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dilger, K | 1 |
| Metzler, J | 1 |
| Bode, JC | 1 |
| Klotz, U | 1 |
| Mishin, VM | 1 |
| Rosman, AS | 1 |
| Basu, P | 1 |
| Kessova, I | 1 |
| Oneta, CM | 1 |
| Lieber, CS | 1 |
| Gouillon, Z | 1 |
| Lucas, D | 1 |
| Li, J | 1 |
| Hagbjork, AL | 1 |
| French, BA | 1 |
| Fu, P | 1 |
| Fang, C | 1 |
| Ingelman-Sundberg, M | 1 |
| Donohue, TM | 1 |
| French, SW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone When Administered Individually or Concurrently[NCT05257447] | Phase 1 | 19 participants (Actual) | Interventional | 2022-04-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for chlorzoxazone and Liver Diseases, Alcoholic
| Article | Year |
|---|---|
CYP2E1 activity in patients with alcoholic liver disease.
Topics: Adult; Aged; Chlorzoxazone; Cytochrome P-450 CYP2E1; Female; Humans; Liver Diseases, Alcoholic; Male | 1997 |
Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans.
Topics: Alcoholism; Biomarkers; Chlorzoxazone; Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Liv | 1998 |
Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole.
Topics: Animals; Apoenzymes; Body Weight; Chlormethiazole; Chlorzoxazone; Chymotrypsin; Cysteine Endopeptida | 2000 |